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Abstract 
During the process of matrix vesicle (MV)-mediated initiation of mineralisation, chondrocytes 
and osteoblasts mineralise the extracellular matrix by promoting the seeding of basic calcium 
phosphate crystals of hydroxyapatite (HA) along the collagen fibrils. This orchestrated pro-
cess is carefully regulated by the balanced action of propagators and inhibitors of calcification. 
The primary antagonistic regulators of extracellular matrix mineralisation are phosphate (Pi) 
and inorganic pyrophosphate (PPi). Studies in mouse models and in humans have established 
critical roles for Pi/PPi homeostasis in biomineralisation. In this review, we present the reg-
ulators of Pi/PPi, as derived from animal models, and discuss their clinical relevance to 
physiological and pathological mineralisation. 
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Introduction 
During  skeletogenesis  and  bone  development, 
osteoblasts  from  bones,  as  well  as  hypertrophic 
chondrocytes from embryonic or growth plate carti-
lages,  mineralise  the  extracellular  matrix  (ECM)  at 
least in part by promoting the deposition of HA crys-
tals  in  the  sheltered  interior  of  the  mem-
brane-bounded matrix vesicles (MVs). The MVs are 
submicroscopic,  extracellular,  membrane-invested 
bodies containing calcium and phosphate (Pi) and are 
released  from  the  apical  microvilli  of  hypertrophic 
chondrocytes [1-2] or osteoblasts [3-4]. Once released, 
the MVs serve as nucleation sites and continue to ac-
cumulate  calcium  and  Pi,  which  stimulate  the  for-
mation  of  HA  crystals  from  the  immature  minerals 
present in the lumen and initiate mineralisation [1, 3, 
5]. In a second step, the MV membranes subsequently 
rupture and/or break down, and the HA crystals are 
exposed  to  the  extracellular  fluid  and  continue  to 
propagate along the extracellular collagen fibrils [6]. 
This  MV-mediated  mineralisation  is  coordinated  by 
the balanced action of propagators and inhibitors of 
calcification. Studies of the mechanisms involved in 
the regulation of physiological and pathological min-
eralisation have indicated that the Pi/PPi homeostasis 
is  the  main  determinant  of  the  rate  of  HA  crystal 
formation  in  bone  tissue  [7].  The  extracellular  PPi 
(ePPi) adsorbs tightly to HA and potently antagonises 
the ability of Pi to crystallise with calcium to form HA, 
thereby  inhibiting  HA  crystal  propagation  [8].  For 
normal mineral deposition to proceed, a tight balance 
between the Pi and PPi levels must be maintained.  
The MVs perform specialised roles in initiating 
matrix mineralisation. These roles include regulating 
the Pi/PPi ratio in the intra- and extracellular fluid, 
managing mineral nucleation, controlling calcium and 
Pi  ion  homeostasis,  and  interacting  with  the  sur-
Ivyspring  
International Publisher   Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
779 
rounding ECM to direct HA localisation and growth 
[1, 9-11]. The MVs possess protein and lipid machin-
ery that is essential to carry out these functions, and 
they  are  highly  enriched  in  certain  mineralisa-
tion-relevant  proteins,  especially  tissue-nonspecific 
alkaline  phosphatase  (TNSALP/ALPL/Akp2), 
ATPase,  AMPase,  inorganic  pyrophosphatase,  ecto-
nucleotide  pyrophosphatase  phosphodiesterase  1 
(NPP1/PC-1/Enpp1),  phosphatase  orphan  1 
(PHOSPHO1),  sodium-dependent  Pi  symporters 
(Pit1/2), and annexins [12-14]. An emerging consen-
sus  now  emphasises  the  central  role  of  these  MV 
proteins,  in  conjunction  with  the  cell-associated  an-
kylosis protein (ANK), in the physiological manipu-
lation of Pi/PPi homeostasis and in the control of os-
teopontin (OPN) [7, 15-16].  
In this article, we discuss the regulators of Pi/PPi 
homeostasis,  as  determined  from  various  mouse 
models, and how they relate to pathological or ectopic 
mineralisation. The models presented in this context 
will enable us to investigate and clarify the functional 
involvement of the highlighted MV-related proteins 
in skeletal mineralisation and soft tissue ossification 
abnormalities. This discussion will help to elucidate 
the mechanism of action for diseases such as hypo-
mineralisation, hypermineralisation, and ectopic ossi-
fication. 
Roles of TNSALP, NPP1, and ANK in PPi 
metabolism and mineralisation 
PPi is a major inhibitor of physiologic and path-
ologic  calcification,  bone  mineralisation,  and  bone 
resorption [17]. The maintenance of physiologic ePPi 
levels  by  mineralisation-competent  cells  suppresses 
spontaneous calcification, and abnormal ePPi metab-
olism  has  been  implicated  in  abnormal  calcification 
[18]. Decreased PPi concentrations can generate basic 
calcium phosphate (BCP) deposition, while an excess 
of PPi can lead to calcium pyrophosphate dihydrate 
(CPPD) formation, a marker of pathological calcifica-
tion [18]. Given that MV-associated proteins are pri-
marily  responsible  for  producing  and  hydrolysing 
ePPi, the functional disruption of MV-associated en-
zymes and PPi transporters in mice and the observa-
tion of MV-related gene deficiencies in  humans are 
anticipated  to  cause  phenotypic  changes  associated 
with defective skeletal mineralisation.  
TNSALP 
TNSALP, which is encoded by the Akp2 gene, is 
a  membrane-bound  phosphomonoesterase  localised 
to  the  surface  of  osteoblasts  and  chondrocytes,  in-
cluding the membranes of their shed MVs, via a gly-
cosylphosphatidylinositol  (GPI)  anchor  [19-20].  The 
absence of TNSALP activity results in the extracellular 
accumulation  of  its  natural  substrates,  such  as  py-
ri-doxal-5'-phosphate  (PLP),  phosphoethanolamine 
(PEA), and PPi [20-21]. Mutations in the Akp2 gene 
cause the inherited skeletal disease known as hypo-
phosphatasia  (HPP),  which  is  characterised  by  hy-
pomineralisation  that  causes  rickets  in  infants  and 
children,  osteomalacia  in  adults,  spontaneous  frac-
tures, deficiencies in serum and bone alkaline phos-
phatase  (ALP)  activity,  and  elevated  extracellular 
concentrations of PPi [22-23]. The severity of the six 
clinical forms of HPP varies widely in patients and is 
modulated by the nature of the Akp2 mutation. Pa-
tients  with  the  infantile  form  of  HPP  may  appear 
normal before the onset of failure to thrive and the 
associated  development  of  rickets  before  the  first  6 
months, and severe infantile HPP is often fatal [23]. To 
date, cell therapy with bone marrow cells [24-25] and 
mesenchymal cells [26] have been showed very lim-
ited or no clinical effects to HPP. Very recently, en-
zyme replacement, using ENB-0040, a bone-targeted 
form of human TNALP, can improve skeletal mani-
festations  and  pulmonary  and  physical  function  in 
life-threatening HPP [27]. 
TNSALP  knockout  mice,  which  serve  as  good 
models for the infantile form of HPP, have been es-
tablished  in  two  independent  laboratories  [28-29]. 
Biochemical, radiographic, and histological investiga-
tions have shown that Akp2−/− mice are born with a 
normal  skeletal  phenotype  but  develop  rachitic 
changes,  osteopenia,  and  growth  plate  chondrocyte 
differentiation  arrest.  Subsequently,  the  animals 
manifest secondary hyperparathyroidism and epilep-
tic seizures, and they die prematurely due to the mul-
tiple  metabolic  abnormalities  caused  by  the  lack  of 
TNSALP and the resulting elevated concentrations of 
its substrates, including PLP, PEA, and PPi [29-30]. A 
subsequent study of Akp2−/−  mice revealed that, in 
addition to the hypomineralisation of the skeleton, a 
severe disorder of the mineral crystal alignment pat-
tern existed in the corticalis of growing long bones. 
This  defect  was  also  associated  with  a  disordered 
matrix architecture, which was presumably caused by 
disturbed bone remodelling [31]. Recently, two strat-
egies for therapy in Akp2−/− mice have been reported. 
Sustained delivery of bone-targeted form of TNSALP 
prevented infantile HPP in Akp2−/− mice; and lenti-
viral  gene  therapy  during  the  neonatal  period  pro-
longed survival and corrected the phenotype  of se-
vere infantile HPP in Akp2−/− mice [21, 32]. Interest-
ingly, there were no differences observed between the 
TNSALP-knockout  mice  and  wild-type  littermates 
immediately  after  birth  [7-9];  perhaps  maternal 
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expressed  in  utero  can  compensate  for  the  lack  of 
TNSALP during embryogenesis in Akp2−/− mice [30, 
33].  Primary  osteoblasts  from  the  calvaria  of 
TNALP-knockout mice differentiate normally in vitro 
and display a normal level of mRNA expression and 
protein  synthesis  of  osteocalcin  (OC)  and  collagen 
type I, but they fail to form mineralising nodules in 
vitro [34]. Electron microscopy revealed that, in both 
humans  and  mice,  TNSALP-deficient  MVs  contain 
apatite  crystals  but  are  characterised  by  increased 
levels of unhydrolysed PPi and an absence of mineral 
crystal  proliferation  and  growth  in  the  matrix  sur-
rounding  the  MVs.  These  findings  indicate  that 
TNSALP  is  involved  but  not  essential  in  the  initial 
step of mineralisation within MVs [19]. 
In  addition,  transgenic  overexpression  of 
TNSALP can cause a decrease in ePPi concentrations 
that induce spontaneous HA crystal formation within 
a  fibrillar/collagenous  scaffolding  [7,  15,  35].  These 
findings appear to support the hypothesis that high 
PPi levels at the perimeter of TNSALP-deficient MVs 
prevent crystal growth in the localised region of the 
matrix. Although the TNSALP-deficient MVs may be 
able to initiate intravesicular mineralisation through 
the compensatory activity of other phosphatases hy-
drolysing other substrates to generate Pi, still incapa-
ble to remove excess PPi. Thus, despite TNSALP de-
ficiency,  initial  mineralisation  could  begin  within 
MVs, while its propagation at the perimeter of MVs 
would be hindered by a local excess of PPi. The main 
cause of the hypomineralisation observed in TNSALP 
knockout mice is likely due to the excessive accumu-
lation of PPi in the extracellular matrix [7], suggesting 
that TNSALP is required to promote calcification by 
removing PPi, which inhibits mineralisation [8, 12].  
Recently,  a  novel  mouse  model  of  autosomal 
semi-dominant adult HPP has been developed [36]. In 
contrast to Akp2−/− mice, the Akp2Hpp/Hpp mice were 
characterised  by  a  normal  lifespan,  absence  of  sei-
zures  and  normal  initial  skeletal  development  and 
growth,  but  developed  late-onset  skeletal  diseases 
[36].  Compared  with  wild  type  control  cells,  osteo-
blasts  from  Akp2Hpp/Hpp  mice  displayed  ∼10%  of 
normal ALP activity, and significant reductions in the 
levels of iPi, but normal ePPi levels, yet were capable 
of normal mineralisation in short term in vitro [36]. 
These  data  indicated  that  the  action  of  residual 
TNSALP  activity  contributed  to  the  normal  pheno-
type  of  young  Akp2Hpp/Hpp  mice,  but  fell  bellow  a 
threshold needed to maintain normal bone turnover 
with age. 
NPP1 
PPi is primarily generated by the members of the 
nucleotide  pyrophosphatase/phosphodiesterase 
(NPP)  family  of  isozymes,  including  NPP1, 
NPP2/autotaxin, and NPP3/B10 [8]. However, NPP1 
appears to be the only NPP present in MVs [37]. Sim-
ilar  to  the  skeletal  expression  of  TNSALP,  NPP1, 
which is encoded by the Enpp1 gene, is highly abun-
dant on the surfaces of osteoblasts and chondrocytes, 
as well as on the membranes of their MVs [38]. NPP1 
potently  inhibits  the  nucleation  and  propagation  of 
HA and other BCP crystals through its PPi-generating 
properties [8]. In humans, loss-of-function NPP1 mu-
tations  cause  ectopic  ossification  diseases,  such  as 
autosomal  recessive  hypophosphatemic  rickets 
(ARHR2; OMIM No. 613312), ossification of the pos-
terior  longitudinal  ligament  (OPLL;  OMIM 
No.602475),  and  generalised  arterial  calcification  of 
infancy (OMIM No. 208000) [39-41].  
In  naturally  occurring  mouse  models,  the  link 
between defective NPP1 expression and altered min-
eralisation  was  initially  demonstrated  in  tip-
toe-walking  ttw/ttw  mice,  which  are  caused  by  a 
nonsense mutation (glycine 568 to stop) in the NPP1 
gene [42]. The truncated NPP1 protein loses a vital 
calcium binding domain and two putative glycosyla-
tion sites. The ttw/ttw mice display marked ectopic 
ossification, including the postnatal development of 
progressive ankylosing intervertebral and peripheral 
joint hyperostosis, as well as spontaneous arterial and 
articular cartilage calcification and increased vertebral 
cortical bone formation [42-46]. Excess axial skeleton 
ligamentous  calcification  results  in  myelopathy  and 
abnormal  gait  in  ttw/ttw  mice,  reminiscent  of  the 
human  disorder  OPLL  [47].  Additionally,  ttw/ttw 
mice  exhibit  abundant  calcified  matrix  vesicle-like 
chain granules in the pericellular matrix, cytoplasm, 
and nucleus of the articular and spinal disc chondro-
cytes, suggesting that NPP1 deficiency may dysregu-
late matrix vesicle formation and/or calcification [48]. 
The ttw/ttw mice also share features with idiopathic 
infantile arterial calcification, including spontaneous 
periarticular and aortic calcifications in early life and 
the systemic lowering of NPP1 activity and PPi levels 
[42, 49-50].  
Consistent with the findings from ttw/ttw mice, 
chondrogenesis mediated by PPi depletion promotes 
spontaneous aortic calcification in Enpp1−/− mice [51]. 
The  multipotential  bone  marrow  stromal  cells  from 
Enpp1−/− mice can spontaneously undergo chondro-
genesis; and the cartilage-specific expression of genes, 
such as ALP and OPN, was altered in aortic smooth 
muscle cells, which showed increased calcification in 
Enpp1−/− mice [51]. Enpp1−/− mice are characterised 
by  spontaneous  mineralisation  of  soft  tissue,  hy-
permineralisation in the talocrural joint and the cor-Int. J. Biol. Sci. 2012, 8 
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tical thickness of both the tibia and femur, which be-
comes increasingly more severe with age [52]. These 
serious disruptions to the architecture and minerali-
sation of the long bones were consistent with altera-
tions in the markers of bone formation and resorption 
and  explained  their  reduced  mechanical  properties 
[52]. These findings suggest that NPP1 is essential for 
normal  bone  development  and  for  the  control  of 
physiological  bone  mineralisation  with  age  through 
PPi production. Interestingly, the Enpp1−/− mice have 
also been documented to display trabecular bone loss 
[52]. Furthermore, circulating phosphate and calcium 
levels  were  reduced,  and  the  concentration  of  the 
phosphaturic hormone FGF-23, which is elevated in 
ARHR2,  was  also  significantly  increased  in  the 
Enpp1−/− mice [40, 52]. It should be noted that NPP1 
also plays important roles in calcium and phosphate 
regulation and the repression of soft tissue minerali-
sation, as well as in maintaining skeletal structure and 
function [52]. Moreover, it has recently been demon-
strated that NPP1 regulates osteoblastic gene expres-
sion and controls cellular differentiation in calvarial 
osteoblasts independent of its catalytic activity [53]. 
ANK 
ANK, which is encoded by the mouse progres-
sive  ankylosis  (ank)  gene,  appears  to  function  as  a 
multiple-pass,  transmembrane  PPi-channelling  pro-
tein,  allowing  PPi  molecules  to  pass  through  the 
plasma membrane from the cytoplasm to the outside 
of  the  cell  [54-55].  Unlike  TNSALP  and  NPP1,  the 
ANK protein is detectable on the surfaces of the os-
teoblasts and chondrocytes but not on the surfaces of 
osteoblast-derived MVs [35]. Mutations in the human 
ANK gene (ANKH), specifically the point mutations 
that cluster  mostly in cytoplasmic domains close to 
the C terminus, have previously been linked to cra-
niometaphyseal dysplasia (CMD; OMIM No.123000) 
[56-57]. CMD is a childhood disease characterised by 
several craniofacial anomalies, including hyperostosis 
and sclerosis of the skull and symmetric thickening of 
all  facial  bones.  In  severe  cases,  hyperostosis  and 
sclerosis of the skull may lead to cranial nerve com-
pressions,  resulting  in  hearing  loss  and  facial  palsy 
[57].  The  results  from  two  studies  analysing  CMD 
mutations  indicated  that,  other  than  acting  as  a 
transporter,  ANK  may  perform  one  or  more  addi-
tional functions in the regulation of bone formation 
and remodelling [56-58]. Mutations in the N terminus 
of ANKH result in another human skeletal disorder, 
familial calcium pyrophosphate dihydrate deposition 
disease (CPPDD), also known as familial chondrocal-
cinosis (OMIM No.118600), which is characterised by 
the formation of CPPD crystals in articular cartilage, 
but unlike CMD, does not present with apparent de-
fects in the skull or long bones [59-61]. 
A spontaneous mutation in the murine ank gene 
is a loss-of-function mutation [62]. These ank muta-
tion mice display a generalised, progressive form of 
arthritis  accompanied  by  mineral  deposition,  the 
formation of bony outgrowths, and joint destruction 
[54]. Fibroblasts from the ank/ank mutant mice show 
a  three-  to  five-fold  decrease  in  ePPi  levels  and  an 
increase  in  intracellular  PPi  (iPPi)  accumulation 
compared with wild type cells. These results indicate 
that the mouse ank gene regulates tissue calcification 
and  the  development  of  arthritis  in  higher  animals 
through the control of PPi levels [54]. A recent bio-
chemical study used a sensitive radioflux method to 
test  the  transport  activity  of  mutant  ANK  proteins 
carrying CMD mutations (C331R and C389R) in frog 
oocytes  and  showed  greatly  reduced  PPi  transport 
activity  [55].  However,  the  pathophysiological 
mechanisms in human CPPDD and in ank/ank mice 
are distinct. In human CPPDD, mutant ANK proteins 
have been characterised as gain-of-function mutations 
that result in increased ePPi levels [59, 63]. The high 
concentration  of  ePPi  in  joint  fluid  inhibits  the  for-
mation of HA crystals and promotes the deposition of 
CPPD crystals within joint tissues, ultimately leading 
to cartilage destruction. However, another study re-
ported  that  the  number  of  mature  osteoblasts  and 
osteoclasts was reduced, and the bone formation, as 
well as bone resorption was suppressed in Ankank/ank 
mice. This finding indicated that ANK can also regu-
late bone remodelling through directly affecting os-
teoblast and osteoclast differentiation [62]. 
Mice with complete and joint-specific disruption 
of Ank gene function (Anknull/null and Ankank/ank) were 
generated  simultaneously  to  verify  whether  Ank 
mutations could completely eliminate the function of 
the endogenous gene [64]. Two Ank loss-of-function 
models had joint and skeletal defects of similar sever-
ity, with increased HA deposition eventually leading 
to  complete  rigidity  and  death  at  approximately  6 
months of age [64-66]. The study indicated that both 
complete and joint-specific loss of ANK function can 
cause mineral formation in joints and confirms a key 
role for Ank in joint maintenance and local regulation 
of mineralisation in articular cartilage [64]. In addi-
tion, Anknull/null mice shared some characteristics with 
CMD patients but did not fully replicate the symp-
toms of the human condition. The phenotype differ-
ences  between  Anknull/null  mice  and  CMD  patients 
indicate that the pathological mechanism in  human 
CMD  is  not  merely  due  to  a  loss  of  PPi  transport 
function by ANK [55].  
Recently,  the  first  knock-in  (KI)  mouse  model Int. J. Biol. Sci. 2012, 8 
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(AnkKI/KI) of CMD was generated [67]. The animals 
express one of the most common Ank mutations (i.e., 
the Phe 377 deletion) identified in the human disease. 
Homozygous AnkKI/KI mice share many features with 
human CMD patients, including hyperostosis of cra-
niofacial bones, massive jawbones, decreased diame-
ter of the cranial foramina, the obstruction of the nasal 
sinuses,  the  fusion  of  the  middle  ear  bones,  and 
club-shaped  femurs  [67].  Surprisingly,  despite  the 
hyperostotic phenotype, the bone matrix in AnkKI/KI 
mice is hypomineralised and less mature. Although 
the number of osteoclasts was increased in AnkKI/KI 
mice,  as  determined  by  histomorphometry,  the  in 
vitro cultures of bone marrow-derived macrophages 
showed  decreased  osteoclastogenesis  [67].  Subse-
quently, an elaborate study was carried to investigate 
the effects of the ANK Phe377del mutation on osteo-
blastogenesis  and  osteoclastogenesis  at  the  cellular 
level in the AnkKI/KI mouse model [68]. AnkKI/KI os-
teoblast  cultures  showed  decreased  expression  of 
genes involved in mineral deposition and bone min-
eralisation  regulation  (e.g.,  Mmp13,  Ocn,  Osx,  and 
Phex) and increased NPP1 activity, while the Fgf23 
mRNA  level  was  elevated  in  calvarial  and  femoral 
bones.  Similar  to  the  bone  marrow-derived  macro-
phage cultures from AnkKI/KI mice, peripheral blood 
cultures from CMD patients exhibited reduced osteo-
clastogenesis. Cell-autonomous effects in the AnkKI/KI 
osteoclasts caused disrupted actin ring formation and 
cell fusion [68]. Moreover, the osteoblasts of AnkKI/KI 
mice failed to adequately support osteoclastogenesis. 
The  authors  concluded  that  the  hypomineralisation 
and  high  bone  mass  phenotypes  of  AnkKI/KI  mice 
were due to impaired osteoblastogenesis and osteo-
clastogenesis resulting from the ANK Phe377del mu-
tation [68]. 
Roles of PHOSPHO1 and PiT-1/2 in Pi me-
tabolism and mineralisation 
There are two extracellular mineral ions, Pi and 
Ca2+, that play a critical role in the regulation of ECM 
mineralisation. Mutations in genes regulating Pi/Ca2+ 
homeostasis have resulted in severe skeletal mineral-
isation abnormalities in mouse models [13]. Interest-
ingly, the ECM mineralisation defects were invariably 
associated with low Pi levels but not always with low 
serum calcium levels, suggesting that the regulation 
of the systemic Pi levels is indispensable for proper 
bone formation, particularly for the osteoid minerali-
sation processes. In the MVs, the presence of Pi, gen-
erated from PHOSPHO1 and PiT1/2 as well as from 
ATPase and ADPase, allows for the formation of HA 
crystals when Ca2+ is available [18]. 
PHOSPHO1 
 The phosphatase PHOSPHO1, first identified in 
the chick, exhibits high specific activities for PEA and 
phosphocholine (PChol) [69-71]. PEA and PChol are 
the two most abundant phosphomonoesters in carti-
lage [72], and PHOSPHO1 is expressed at levels ap-
proximately  100-fold  higher  in  mineralising  chon-
drocytes than in the non-skeletal tissues [71]. These 
facts  led  us  to  hypothesise  that  PHOSPHO1  is  re-
sponsible for generating Pi for skeletal mineralisation 
through its highly specific phosphohydrolase activity. 
The presence of PHOSPHO1 within the lumen of the 
MVs has been proven [73]. The data from an expres-
sion  analysis  of  an  embryonic  chick  skeleton  sug-
gested that PHOSPHO1 expression occurs in the di-
aphysis of long bones [73]. Inhibition of PHOSPHO1 
through  the  use  of  novel  small  molecule  inhibitors 
decreased  the  mineralisation  capacity  of  the  MVs, 
which  further  indicated  that  PHOSPHO1  plays  an 
important  role  in  controlling  the  first  step  of  HA 
crystal  deposition  inside  the  MVs  by  generating  Pi 
inside the MVs [73-74]. In addition, PHOSPHO1 also 
has  a  functional  role  in  mineralisation  during  limb 
development.  Inhibition  of  PHOSPHO1  activity  re-
sults  in  impaired  skeletal  endochondral  mineralisa-
tion  during  limb  development  in  the  chick  [75].  To 
date, no human disease has been associated with a 
Phospho1 mutation.  
Very recently, Phospho1−/− mouse models have 
been generated to study the role of PHOSPHO1 dur-
ing endochondral ossification [76]. The Phospho1−/− 
mice  exhibited  growth  plate  abnormalities,  sponta-
neous fractures, bowed long bones, osteomalacia, and 
scoliosis  in  early  life.  Chondrocytes  and  chondro-
cyte-derived  MVs  from  Phospho1−/−  tibial  growth 
plate  displayed  a  reduced  ability  to  form  minerals, 
which is consistent with the reduced mineralisation of 
their  skeletons.  These  findings  clearly  demonstrate 
that PHOSPHO1 is required for normal endochondral 
ossification [76].  
PiT1/2 
Type III sodium/phosphate cotransporters (i.e., 
PiT1 and PiT2) utilise the free energy provided by the 
Na+ concentration gradient to mediate the influx of Pi 
across  the  cell  membrane.  The  cotransporters  share 
similar gene structures and functional characteristics 
[18, 77-78]. PiT1 and PiT2 are expressed in most or-
gans, suggesting a “housekeeping” function for these 
genes [78-79].  
Recent reports have suggested that PiT1 plays an 
important  role  in  vascular  and  bone  physiology 
[80-81], whereas PiT2 has a role in renal Pi reabsorp-
tion [82-83]. Using in situ hybridisation to study mu-Int. J. Biol. Sci. 2012, 8 
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rine  metatarsals,  PiT-1  mRNA  was  found  to  be  ex-
pressed in early hypertrophic chondrocytes, which is 
consistent with a potential role for the PiT-1 cotrans-
porter in matrix calcification [84]. PiT1 plays a domi-
nant  role  in  the  transdifferentiation  of  the  vascular 
smooth muscle cells (VSMCs) to osteoblast-like cells 
during the process of vascular calcification [80, 85]. 
The  knockdown  of  PiT-1  in  human  VSMCs  sup-
pressed phosphate-induced mineralisation and oste-
ochondrogenic  changes,  which  were  rescued  by 
overexpression  of  mouse  PiT-1  using  PiT-1-specific 
small  interfering  RNAs  (siRNAs)  [86].  PiT-1  was 
found to be required for the phosphate-induced calci-
fication of human VSMCs in vitro [80]. A recent study 
of Werner Syndrome patients with subcutaneous cal-
cification found that PiT-1 was overexpressed in the 
patients’ skin, thereby supporting a role for PiT-1 in 
diseases  characterised  by  ectopic  calcification  [87]. 
However,  the  transgenic  overexpression  of  PiT-1  in 
rats affected bone and calcium phosphate metabolism 
and ALP activity, but did not influence bone matrix 
mineralisation  or  skeletal  development,  potentially 
due  to  the  effects  of  an  unidentified  compensatory 
mechanism [88].  
PiT-1 knockout mice have been recently gener-
ated  by  two  different  groups  to  understand  the 
physiological role of these transporters. The complete 
deletion of PiT1 resulted in embryonic lethality. PiT-1 
null embryos arrested between embryonic days 11.5 
and 13.5 and displayed severe anaemia [89-90]. The 
anaemia may result from the decreased proliferation 
and massive apoptosis of the fetal liver, but a funda-
mental defect in hematopoiesis has not yet been ruled 
out [90]. However, observations  of the vascular de-
velopment of the yolk sac yielded contradictory re-
sults in these two studies. Although PiT1 is essential 
to embryonic development, the protein does not ap-
pear to be essential for skeleton and vasculature de-
velopment  in  PiT1-deficient  mice  [90].  The  role  of 
PiT-1  in  the  bone  development  or  calcification  pro-
cesses cannot be addressed in these null embryos, but 
the approach used to generate conditional alleles for 
PiT-1  would  be  valuable  in  the  creation  of  tis-
sue-specific knockouts. In addition, the development 
of a model with a hypomorphic PiT-1 allele  would 
allow for the analysis of subtle phenotypes that are 
determined by the gene expression level [80]. To date, 
no PiT-2 knockout mice have been reported. 
Discoveries from double-knockout mouse 
models  
The restriction of mineral deposition to specific 
sites in the skeletal tissues and the regulation of the 
mineralisation  process  are  crucial  in  maintaining  a 
healthy  skeleton  [12-13].  Normal  mineralisation  is 
dependent on a balance between the intra- and extra-
cellular  levels  of  Pi  and  PPi  [9].  The  ePPi  pool  has 
been hypothesised to determine the rate of HA crystal 
formation  in  the  bone  tissue,  whereas  the  action  of 
TNSALP, NPP1 and ANK are proposed to regulate 
the  PPi  concentration.  Akp2−/−,  Enpp1−/−,  and 
ank/ank  mice  all  suffer  from  severe  mineralisation 
defects  due  to  abnormal  PPi  levels.  The  concerted 
action of TNSALP, NPP1, and ANK ensures that the 
optimal concentration of PPi is achieved under phys-
iologic  conditions,  and  double-knockout  mice  have 
been valuable in furthering our understanding of the 
roles  that  these  proteins  play  in  the  MV-mediated 
process of bone mineralisation.  
[Akp2
−/−; Enpp1
−/−] 
TNSALP is proposed to be required to hydrolyse 
PPi  at  the  site  of  mineral  crystal  proliferation,  thus 
facilitating mineral precipitation and growth, and is 
also  required  to  contribute  to  the  ePi  pool  for  the 
formation of HA crystals [8, 12, 19]. Mutations in the 
TNSALP gene in humans and mice result in a meta-
bolic disease known as  hypophosphatasia, which is 
characterised  by  hypomineralisation  and  elevated 
ePPi levels. In NPP1 deficiencies, the ePPi pool de-
creases because of reduced PPi production, and hy-
permineralisation  occurs  in  the  absence  of  the  HA 
deposition  inhibitor,  PPi.  Interestingly,  the  double 
knockout  of  both  Akp2  and  Enpp1  [Akp2−/−; 
Enpp1−/−] rescued the bone mineralisation abnormal-
ities of the individual mutations, including the hypo- 
and hypermineralisation defects in the calvaria and 
spine [7]. The MVs derived from the double-knockout 
mouse osteoblasts showed normalisation of the ePPi 
content and mineral deposition. These findings sug-
gest that TNSALP and NPP1 are antagonistic regula-
tors that are directly involved in fine-tuning the PPi 
concentration  to  maintain  steady-state  levels  of  PPi 
adequate for controlled mineralisation. Further, this 
evidence points to both NPP1 and TNSALP as poten-
tial therapeutic targets in the treatment of mineralisa-
tion diseases such as hypophosphatasia and osteoar-
thritis [7].  
However, when considering the trabecular bone 
loss  of Enpp1-deficient  mice, in addition to the hy-
permineralisation of soft tissue [42, 45, 52], the extent 
of  mineral  deposition  in  the  bones  of  [Akp2−/−; 
Enpp1−/−]  needed  to  be  examined  to  ascertain 
whether correction of  the  mineralisation abnormali-
ties in the [Akp2−/−; Enpp1−/−] mice extend to the en-
tire skeleton [91]. The effects of the Enpp1 ablation on 
an Akp2−/− background were site-specific and extends 
only to the calvaria, spine, and incompletely in the Int. J. Biol. Sci. 2012, 8 
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femur and tibia in which the [Akp2−/−; Enpp1−/−] mice 
were  much  more  worse  than  in  the  Enpp1−/− mice 
[91]. In contrast to the rescue of the phenotype in the 
calvaria, vertebrae, and soft tissues as a consequence 
of the simultaneous disruption of NPP1 and TNSALP 
function, the  long bones  of the [Akp2−/−; Enpp1−/−] 
mice  appeared  to  have  sustained  osteomalacia.  The 
hypomineralisation  observed  in  the  long  bones  of 
Enpp1−/− mice may be related to the different levels of 
NPP1 expression in these skeletal environments; that 
is,  endogenous  NPP1  expression  is  relatively  low 
surrounding the long bones in comparison with the 
calvaria and vertebrae [52, 91]. Thus, with the com-
plete  disruption  of  NPP1  function,  the  long  bones 
could show further reductions in ePPi to abnormally 
low levels, resulting in insufficient PPi substrate levels 
for  TNSALP  to  generate Pi  for  normal  mineral  for-
mation.  Because  inadequate  quantities  of  PPi  are 
generated from NPP1 or hydrolysed by TNSALP, the 
[Akp2−/−;  Enpp1−/−]  mice  displayed  sustained  more 
severe osteomalacia of the long bones compared to the 
Enpp1−/− mice [91]. 
[Akp2
−/−; Ank/Ank] 
Given that the ANK protein functions similarly 
to  NPP1,  albeit  in  a  different  manner,  [Akp2−/−; 
Ank/Ank]  mice  were  generated  to  investigate 
whether the simultaneous disruption of TNSALP and 
ANK functions would also rescue the mineralisation 
defects of the mice with single gene ablations [35]. The 
[Akp2−/−; Ank/Ank] mice displayed a partial correc-
tion  of  the  hypo-  and  hypermineralisation  pheno-
types, as measured by the extent of mineralisation in 
their vertebral apophyses. This partial rescue of the 
mineralisation defects observed in the single mutants 
was  associated  with  a  partial  correction  of  the  PPi 
levels.  The  ePPi  concentration  was  normal  in  these 
double mutants, but the iPPi levels remained abnor-
mal [35]. This residual phenotypic abnormality may 
be due to the abnormal iPPi concentration, suggesting 
the importance of a balanced ePPi/iPPi ratio in the 
regulation of HA deposition.  
In  addition,  the  ectopic  calcification  and  soft 
tissue ossification phenotypes were more severe in the 
Enpp1−/− mice than in the ank/ank mice. The degree 
of soft-tissue ossification was further increased in the 
[Enpp1−/−;  Ank/Ank]  double-mutants  compared  to 
the  mice  with  single  gene  ablations  [35].  Together, 
these  observations  and  the  absence  of  ANK  in  the 
MVs  suggest  that  NPP1  is  essential  for  the  second 
phase of mineral deposition and that NPP1 plays a 
more crucial role in PPi production than ANK. Pre-
sumably, there is still a sufficient amount of PPi pro-
vided  by  NPP1  in  the  ank/ank  mice  [35].  This  hy-
pothesis could explain the observed differences in the 
phenotypic abnormalities of the [Akp2−/−; Enpp1−/−] 
and [Akp2−/−; Ank/Ank] mice.  
[Phospho1
−/−; Akp2
−/−] 
It is well established that the first HA crystals are 
formed within the MVs, and TNSALP is not essential 
for the initiation of mineralisation in the MVs because 
the  MVs  from  hypophosphatasia  patients  and 
Akp2−/− mice contain minerals but fail to extend the 
mineral  propagation  beyond  the  MVs  and  into  the 
surrounding  collagenous  matrix  [30].  PHOSPHO1, 
which is sequestered within the MV lumen, has been 
proposed  to  be  responsible  for  the  first  step  of  the 
MV-mediated initiation of mineralisation by increas-
ing  the  intravesicular  Pi  concentration  [74].  Trans-
genic  overexpression  TNSALP  does  not  rescue  the 
skeletal  abnormalities  in  Phospho1−/−  mice,  despite 
correcting their plasma PPi levels. The disruption of 
both  TNSALP  and  PHOSPHO1  in  mouse  embryos 
showed an almost complete absence of skeletal min-
eralisation (i.e., both bone and cartilage), suggesting 
that TNSALP and PHOSPHO1 have independent and 
non-redundant roles for skeletal mineralisation in the 
mouse [76]. It is also worth noting that Phospho1−/− 
mice  showed  small  increases  in  NPP1  activity  and 
ANK  expression,  as  well  as  a  slight  reduction  in 
plasma  TNSALP  levels  [76].  However,  in  a  single 
stillborn [Phospho1−/−; Akp2−/−] pup, some calcifica-
tion was observed in the axial skeleton [76].  
Recently, research was carried out to analyse the 
kinetic  behaviour  of  isolated  wild-type  (WT)  osteo-
blast-derived MVs, as well as TNSALP-, NPP1-, and 
PHOSPHO1-deficient  MVs,  when  confronted  with 
physiologic substrates (e.g., ATP, ADP, and PPi) at the 
physiologic pH [92]. At the MV level, the data indi-
cated that TNSALP was not only an efficient PPiase, 
but it also functioned as a potent ATPase and ADPase. 
In addition to its PPi-generating activity, NPP1 can 
also  act  as  an  efficient  phosphatase,  generating  Pi 
from ATP, ADP, and PPi. However, this activity was 
evident only in the absence of TNSALP [92]. In con-
trast,  when  confronted  with  ATP,  ADP,  and  PPi, 
PHOSPHO1 is not an efficient phosphatase, as it re-
quires cooperation with PiT1/2 to achieve a sufficient 
Pi  concentration  for  crystallisation  in  the  MVs  [92]. 
This research study first proposed that TNSALP has 
major roles as a pyrophosphatase, ATPase, and AD-
Pase, thus participating in the calcification process not 
only by the restricting the concentration of ePPi, but 
also  by  simultaneously  contributing  to  the  Pi  pool 
available for calcification via its ATPase, ADPase, and 
PPiase  functions.  This  new  data  helped  to  explain 
why Akp2−/− mice, which model infantile HPP, dis-Int. J. Biol. Sci. 2012, 8 
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played a normal phenotype immediately after birth 
and had a phenotype that was less severe than the 
lethal and perinatal HPP [23, 30]. Despite the absence 
of TNSALP, NPP1 can act as a backup pyrophospha-
tase  to  control  the  ePPi  concentration,  allowing  the 
Akp2−/−  mice  to  carry  out  normal  mineralisation. 
However,  this  compensatory  effect  was  temporary; 
after few days, the Akp2−/− mice developed progres-
sive hypomineralisation with age [30]. The partial and 
temporary compensatory pyrophosphatase activity of 
NPP1 also explains the partial mineralisation of the 
axial  skeleton  in  the  single  stillborn  [Phospho1−/−; 
Akp2−/−]  pup.  The  deletion  of  PHOSPHO1  would 
depress  intravesicular  Pi  levels,  but  a  sufficient  in-
travesicular Pi concentration can also be achieved by 
the  activity  of  PiT1/2.  The  influx  of  ePi  could  be 
produced  primarily  by  the  ATPase  activity  of 
TNSALP or, in the absence of TNSALP, by the ATPase 
activity  of  NPP1.  This  compensatory  mechanism 
could  explain  why  the  Phospho1−/−  MVs  only  dis-
played a decrease rather than a complete loss of calci-
fication [76].  
Interplay between PPi and OPN in the in-
hibition of mineralisation  
OPN, which was first identified in an osteosar-
coma as a matrix protein with strong mineral binding 
properties [30, 93-94], has been studied as a mineral 
inhibitor that is upregulated by inflammation, ather-
osclerosis, and vascular calcification [95-96]. Recently, 
a link between the proteins regulating ePPi and OPN 
has  been  widely  investigated.  The  ank/ank  and 
Enpp1−/− mice showed a decrease in ePPi and OPN 
levels,  and  the  subsequent  hypermineralisation  was 
particularly associated with the joints and ligaments 
[42, 54, 97]. Extracellular PPi downregulation resulted 
in a concomitant OPN deficiency, and the correction 
of  the  OPN  deficiency  prevents  hypercalcification, 
suggesting the synergistic inhibition of HA deposition 
by PPi and OPN [97]. In addition to being downreg-
ulated in Enpp1−/− and ank/ank mice, OPN expres-
sion was upregulated in Akp2−/− mice and was nor-
malised  in  [Akp2−/−;  Enpp1−/−]  and  [Akp2−/−; 
ank/ank]  mice,  which  corresponded  with  a  full  or 
partial  normalisation  of  mineralisation  defects  and 
PPi  levels  and  suggests  that  PPi  can  regulate  OPN 
expression  [35].  Furthermore,  PPi  modulates  Opn 
expression  in  osteoblasts,  as  the  addition  of  exoge-
nous  PPi  to  WT  calvarial  osteoblasts  caused  an  in-
crease in Opn mRNA level, and down-regulated ex-
pression  of  both  Enpp1  and  Ank[35].  Thus,  it  was 
proposed  that  the  hypo-  and  hypermineralisation 
phenotypes  observed  individually  in  the  Akp2−/− 
mice, Enpp1−/−, and ank/ank mice were due to the 
combined effects of at least two mineralisation inhib-
itors, including PPi and OPN. It is interesting to note 
that the majority of studies reported that Opn−/− mice 
display normal development and bone structure, with 
no  histological  differences  from  WT  mice  [98], 
whereas  other  studies  reported  mild  mineralisation 
abnormalities and more minerals in the Opn−/− mice 
than in WT controls [99-101]. The primary osteoblasts 
from Opn−/− mice showed markedly elevated levels of 
ePPi,  which  were  even  higher  than  in  the  Akp2−/− 
mice, attributable to an increase in Enpp1 and Ank 
expression  and  a  concomitant  downregulation  of 
Akp2  expression  [101].  The  addition  of  exogenous 
OPN  to  Opn−/−  mice  showed  the  opposite  result 
compared to the Opn−/− mice [101]. Thus, OPN likely 
plays a role in ePPi’s production, transport, and deg-
radation through the modulation of Akp2, Ank, and 
Enpp1 expression. Together with the exogenous PPi 
can upregulate Opn expression in WT osteoblasts [35], 
these  datas  indicated  that  there  was  a  feedback 
mechanism  between  PPi  and  OPN.  Recently,  an  in 
vitro study proposed that PPi inhibits the mineralisa-
tion of osteoblast cultures using at least three distinct 
mechanisms,  including  direct  binding  to  minerals, 
increased Opn expression, and decreased ALP activ-
ity, which is consistent with the observations of the 
OPN−/− mice [102]. 
Given  that  both  Akp2−/−  and  Opn−/−  single 
knockout  mice  displayed  elevated  levels  of  ePPi,  it 
was  surprising  that  the  ePPi  levels  of  [Opn−/−; 
Akp2−/−]  mice  were midway between the values of 
these single knockout mice. As previously reported, 
the  Akp2−/−  osteoblast-derived  MVs  contained  only 
half the amount of NPP1 compared with the WT MVs, 
and the transfection of Akp2 up-regulated Enpp1 ex-
pression [97], suggesting that lower NPP1 levels in the 
Akp2−/− mice may contribute the  intermediate ePPi 
levels in the [Opn−/−; Akp2−/−] mice [101]. In addition, 
[Opn−/−; Akp2−/−] mice showed a partial correction of 
the bone hypomineralisation phenotype observed in 
the Akp2−/− mice. These findings, along with the ob-
servation that the [Akp2−/−; Enpp1−/−] and [Akp2−/−; 
ank/ank] mice exhibit corrected PPi and OPN levels, 
support the conclusion that, for a complete rescue of 
the  hypomineralisation  phenotype  in  the  Akp2−/− 
mice, the concentrations of both PPi and OPN must be 
at normal levels [101].  
Conclusions and perspectives 
After  decades  of  investigation,  the  MV-related 
proteins  regulating  Pi/PPi  homeostasis  have  been 
shown to play a prominent role in mineral deposition 
and skeletal development. Studies of animal models 
with  pathologic  calcification  phenotypes  similar  to Int. J. Biol. Sci. 2012, 8 
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those of their human counterparts (Table 1) strongly 
support the hypothesis that ePPi concentration regu-
lates HA crystal deposition and that the Pi/PPi ratio is 
a key factor in the development of either physiological 
or  pathological  mineralisation.  From  a  metabolic 
perspective, ePPi are derived from the TNSALP- and 
NPP1-catalysed  production  of  eATP  as  well  as  by 
intracellular  export  via  ANK  transporters.  Further, 
ePPi is likely to be the source of Pi necessary to sustain 
HA  formation  after  being  cleaved  by  TNSALP  and 
NPP1.  The  intravesicular  mineralisation  propagator 
Pi is generated by the activity of PHOSPHO1, as well 
as by the transport function of PiT1/2 (Figure 1). PPi, 
together with OPN, inhibits HA crystal propagation 
and growth. Mutations of the MV-related proteins can 
affect Pi/PPi homeostasis, HA crystal initiation in the 
MVs,  or  crystal  propagation  along  the  extracellular 
collagen fibrils, resulting in hypomineralisation, hy-
permineralisation,  or  ectopic  ossification  at  various 
ages.  Notwithstanding  our  extensive  knowledge  of 
the involvement of these MV-related proteins in skel-
etal growth, our understanding of the interplay be-
tween TNSALP, NPP1, ANK, PHOSPHO1, and OPN 
in  the  regulation  of  skeletal  mineralisation  during 
growth and aging is incomplete. Other open questions 
regarding  the  functions  of  the  MV-related  proteins 
include  their  roles  in  the  function  of  miner-
al-competent cells and in osteoclastogenesis. The last, 
and perhaps the most important question is how and 
when should intervention occur to manipulate Pi/PPi 
homeostasis with the goal of obtaining a healthy and 
more robust skeleton.  
Table 1. Mouse Models of Regulators of PPi/Pi and Their Human Counterparts. 
Target  Mutant name  Skeletal phenotype  PPi/Pi  OPN  Human counterpart (ref)  Ref 
Akp2  Akp2−/−  Born with normal, Skeletal defective first appeared 
radiographically at ~10 days, hypomineralization, 
progressive rachitic, osteopenia, and fracture 
ePPi↑ 
 
OPN↑  Infantile hypophosphata-
sia 
(OMIM No. 241500) 
[19, 
29-30, 
35] 
  Akp2Hpp/Hpp 
(862 + 5G>A) 
Normal initial skeletal development and growth, 
late onset skeletal diseases, arthropathies 
ePPi N; 
iPi↓ 
  Autosomal Semidominant 
Adult Hypophosphatasia 
(OMIM No. 146300) 
[36] 
Enpp1  Enpp1 (ttw/ttw) 
(1813G>T) 
ankylosing intervertebral, peripheral joint hyper-
ostosis, arterial and articular cartilage calcification 
ePPi↓    Ossification of the poste-
rior longitudinal ligament 
of the spine (OPLL) 
(OMIM No.602475) 
[42, 47] 
  Enpp1−/−  ectopic ossification, disruption to the structural 
and mechanical properties of long bones, severity 
increases with age; trabecular bone loss 
ePPi↓ 
 
OPN↓  Not applicable  [51] 
Ank  AnkKI/KI  hyperostotic phenotype, significantly in craniofa-
cial anomalies, but bone matrix is hypomineraliza-
tion and less mature 
ePPi N    craniometaphyseal dys-
plasia (CMD) (OMIM 
No.123000) 
[67] 
  Anknull/null and 
Ankank/ank 
Arthritis, bony and joint fusion, loss of mobility  ePPi↓;  
iPPi↑ 
 
OPN↓  Not applicable  [35, 64] 
Phos-
pho1 
Phospho1−/−  poor weight gain, growth plate 
and skeletal abnormalities, and thoracic scoliosis 
Intravesicular 
Pi↓; 
ePPi↑ 
  Not applicable  [76] 
PiT1  PiT1Δ5/Δ5 
 
embryonic lethality, no evidence defects in early 
skeleton formation 
    Not applicable  [90] 
Opn  Opn−/−  Normal bone development, but mild mineral dep-
osition 
ePPi↑    Not applicable  [98-99, 
101] 
Double- 
knock-
outs 
[Akp2−/−; 
Enpp1−/−] 
Correct hypo- and hypermineralization in calvaria 
and spine, long bone sustain osteomalacia 
ePPi N  OPN N    [7, 91] 
  [Akp2−/−; 
Ank/Ank] 
partial correction in the hypo- and hyperminerali-
zation 
ePPi N; 
iPPi↑ 
OPN N    [35] 
  [Akp2−/−; 
Phospho1−/−] 
complete absence of skeletal mineralization (bone 
and cartilage) and and perinatal lethality 
Intravesicular 
Pi ↓; 
ePi ↓ 
    [76] 
  [Akp2−/−; 
Opn−/−] 
partial correction of hypomineralization  ePPi↑      [101] 
↑= increase; ↓= decrease; N = normal; OMIM: http://www.ncbi.nlm.nih.gov/omim Int. J. Biol. Sci. 2012, 8 
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Figure 1. Schematic representation of Pi/PPi regulators involved in MV-mediated mineralisation. The HA crystals are composed of Pi and 
Ca2+. In the MVs, Pi is generated by the function of PiT1/2 phosphate transporters, as well as by the hydrolysis of the phosphomonoesters 
PEA and PChol by the phosphatase PHOSPHO1. Ca2+ transport is mediated by annexin channels that allow influx into the vesicles. The 
ePPi pool is derived both by NPP1 catalysing production from eATP and by intracellular export via the ANK transporter at the level of the 
chondrocyte and osteoblast membranes. For both TNSALP and NPP1, ATPase, ADPase and PPiase contribute to the ePi pool, though 
TNSALP is more efficient than NPP1 at the level of the MVs. Moreover, a negative feedback loop exists in intracellular. PPi, which is 
produced by NPP1 and transported by ANK, inhibits the expression of Enpp1 and Ank. PPi, together with its induction of OPN ex-
pression, inhibit HA crystal propagation and growth. 
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phosphoethanolamine;  ARHR2:  autosomal  recessive 
hypophosphatemic rickets; OPLL: ossification of the 
posterior  longitudinal  ligament;  CMD:  crani-
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